Table 2 Evaluation of diagnostic performance of serum BDG (at ≥ 117.7 pg/mL)
Subgroups | Sen (%) | Spe (%) | LR | NPV (%) | PPV (%) |
|---|---|---|---|---|---|
Derivation cohort (n = 121) | 89.01 | 90.00 | 8.900 | 72.97 | 96.43 |
Validation cohort (n = 92) | 76.47 | 91.67 | 9.176 | 57.89 | 96.30 |
≤ 60 years (n = 108) | 89.53 | 95.45 | 19.70 | 70.00 | 78.57 |
> 60 years (n = 105) | 78.08 | 87.50 | 6.247 | 63.63 | 93.44 |
Hematologic malignancies (n = 22) * | 83.33 | 100.0 | 3.333 | 57.14 | 100.0 |
Solid cancer (n = 31) | 80.00 | 100.0 | 9.350 | 73.33 | 100.0 |
Autoimmune or inflammatory disorders (n = 100) | 83.12 | 82.61 | 4.779 | 61.29 | 94.20 |
Interstitial pneumonia (n = 15) * | 66.67 | 100.0 | 2.000 | 42.86 | 100.0 |
Nephrotic syndrome (n = 24) * | 100.0 | 50.00 | 2.000 | 100.0 | 95.65 |
Infectious diseases (n = 14) | 100.0 | 100.0 | 7.000 | 100.0 | 100.0 |
Lung cancer (n = 12) * | 55.56 | 100.0 | 2.000 | 42.86 | 100.0 |